Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Voclosporin eye disorder therapeutic - Aurinia Pharmaceuticals

Drug Profile

Voclosporin eye disorder therapeutic - Aurinia Pharmaceuticals

Alternative Names: Luveniq; LX 211; LX 212; LX 214; Voclosporin ophthalmic solution - Aurinia Pharmaceuticals; VOS

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Isotechnika
  • Developer Aurinia Pharmaceuticals; Lux Biosciences
  • Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Antivirals; Ciclosporins; Eye disorder therapies; Skin disorder therapies; Small molecules; Urologics; Vascular disorder therapies
  • Mechanism of Action Calcineurin inhibitors; Immunosuppressants; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Uveitis
  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Dry eyes
  • Discontinued Blepharitis; Uveitis

Most Recent Events

  • 02 Nov 2020 Suspended - Phase-II/III for Dry eyes in USA (Ophthalmic)
  • 02 Nov 2020 Interim efficacy and adverse events data from a phase II/III AUDREY trial in dry eyes released by Aurinia Pharmaceuticals
  • 08 Oct 2020 Aurinia Pharmaceuticals completes the phase II/III AUDREY trial for Dry eyes in USA (Ophthalmic) (NCT04147650)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top